Advertisement
CGEN or GILD or NKTR
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CGEN’s FA Score shows that 1 FA rating(s) are green whileGILD’s FA Score has 4 green FA rating(s), and NKTR’s FA Score reflects 0 green FA rating(s).
- CGEN’s FA Score: 1 green, 4 red.
- GILD’s FA Score: 4 green, 1 red.
- NKTR’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CGEN’s TA Score shows that 4 TA indicator(s) are bullish while GILD’s TA Score has 3 bullish TA indicator(s), and NKTR’s TA Score reflects 6 bullish TA indicator(s).
- CGEN’s TA Score: 4 bullish, 5 bearish.
- GILD’s TA Score: 3 bullish, 3 bearish.
- NKTR’s TA Score: 6 bullish, 4 bearish.
Price Growth
CGEN (@Biotechnology) experienced а -5.03% price change this week, while GILD (@Pharmaceuticals: Major) price change was -3.40% , and NKTR (@Biotechnology) price fluctuated +1.56% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.37%. For the same industry, the average monthly price growth was +15.66%, and the average quarterly price growth was +33.77%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.22%. For the same industry, the average monthly price growth was +3.58%, and the average quarterly price growth was +9.84%.
Reported Earning Dates
CGEN is expected to report earnings on Nov 06, 2025.
GILD is expected to report earnings on Oct 23, 2025.
NKTR is expected to report earnings on Aug 07, 2025.
Industries' Descriptions
@Biotechnology (+2.37% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+0.22% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| CGEN | GILD | NKTR | |
| Capitalization | 138M | 90.8B | 429M |
| EBITDA | -14.79M | 10.5B | -97.97M |
| Gain YTD | -1.307 | 18.885 | 77.706 |
| P/E Ratio | 64.00 | 16.20 | N/A |
| Revenue | 27.6M | 27.1B | 87.2M |
| Total Cash | 104M | 7.26B | 219M |
| Total Debt | 2.77M | 25B | 100M |
CGEN | GILD | NKTR | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 64 | 23 | 87 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 18 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 17 | 100 | |
SMR RATING 1..100 | 95 | 29 | 99 | |
PRICE GROWTH RATING 1..100 | 64 | 22 | 34 | |
P/E GROWTH RATING 1..100 | 22 | 100 | 83 | |
SEASONALITY SCORE 1..100 | n/a | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (18) in the Biotechnology industry is somewhat better than the same rating for CGEN (76) and is somewhat better than the same rating for NKTR (83). This means that GILD's stock grew somewhat faster than CGEN’s and somewhat faster than NKTR’s over the last 12 months.
GILD's Profit vs Risk Rating (17) in the Biotechnology industry is significantly better than the same rating for CGEN (100) and is significantly better than the same rating for NKTR (100). This means that GILD's stock grew significantly faster than CGEN’s and significantly faster than NKTR’s over the last 12 months.
GILD's SMR Rating (29) in the Biotechnology industry is significantly better than the same rating for CGEN (95) and is significantly better than the same rating for NKTR (99). This means that GILD's stock grew significantly faster than CGEN’s and significantly faster than NKTR’s over the last 12 months.
GILD's Price Growth Rating (22) in the Biotechnology industry is in the same range as NKTR (34) and is somewhat better than the same rating for CGEN (64). This means that GILD's stock grew similarly to NKTR’s and somewhat faster than CGEN’s over the last 12 months.
CGEN's P/E Growth Rating (22) in the Biotechnology industry is somewhat better than the same rating for NKTR (83) and is significantly better than the same rating for GILD (100). This means that CGEN's stock grew somewhat faster than NKTR’s and significantly faster than GILD’s over the last 12 months.
| CGEN | GILD | NKTR | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 58% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 49% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 35% | 1 day ago 86% |
| TrendWeek ODDS (%) | 1 day ago 89% | 1 day ago 49% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 60% | 1 day ago 76% |
| Advances ODDS (%) | 19 days ago 81% | 12 days ago 58% | 5 days ago 76% |
| Declines ODDS (%) | 1 day ago 89% | 4 days ago 50% | 1 day ago 89% |
| BollingerBands ODDS (%) | 1 day ago 78% | N/A | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 42% | N/A |
Advertisement
GILD and
Correlation & Price change
A.I.dvisor indicates that over the last year, GILD has been loosely correlated with AMGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To GILD | 1D Price Change % | ||
|---|---|---|---|---|
| GILD | 100% | +0.06% | ||
| AMGN - GILD | 49% Loosely correlated | +0.38% | ||
| BMY - GILD | 47% Loosely correlated | -1.41% | ||
| GSK - GILD | 44% Loosely correlated | -0.30% | ||
| ABBV - GILD | 42% Loosely correlated | -2.33% | ||
| PFE - GILD | 42% Loosely correlated | -0.86% | ||
More | ||||